Implementation of GDP for Pharmaceutical Products in Hong Kong
Recommendation

22 October 2026
Good Distribution Practice of Active Substances for Human and Veterinary Medicinal Products
The Pharmacy and Poisons Board of Hong Kong has launched a public consultation on implementing Good Distribution Practice (GDP) for pharmaceutical products in Hong Kong by adopting the PIC/S Guide to Good Distribution Practice.
The proposal aims to strengthen supply chain integrity, align Hong Kong’s regulatory approach with internationally recognised standards and practices, and ensure that medicines are consistently stored, handled and transported under suitable conditions throughout distribution.
The following draft documents were published on the website of the Drug Office of the Department of Health:
- Guide to Good Distribution Practice for Pharmaceutical Products (“GDP Guide”)
- Guidance for Industry: Guide to Good Distribution Practice for Pharmaceutical Products (“Guidance for Industry”)
- Revised Code of Practice for Holder of Wholesale Dealer Licence (“WDL COP”)
According to the consultation documents, GDP would be introduced via additional application requirements and/or licensing conditions for licensed manufacturers and wholesale dealers. Implementation is planned to start with new applicants in Q3 2026 and extend to relevant existing licensees in Q3 2028.
The consultation period runs from 1 April to 31 May 2026. Please also see the Consultation Document for further information.
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September


